Your browser doesn't support javascript.
loading
Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study.
Subbiah, Vivek; Hu, Mimi I; Mansfield, Aaron S; Taylor, Matthew H; Schuler, Martin; Zhu, Viola W; Hadoux, Julien; Curigliano, Giuseppe; Wirth, Lori; Gainor, Justin F; Alonso, Guzman; Adkins, Douglas; Godbert, Yann; Ahn, Myung-Ju; Cassier, Philippe A; Cho, Byoung Chul; Lin, Chia-Chi; Zalutskaya, Alena; Barata, Teresa; Trask, Peter; Scalori, Astrid; Bordogna, Walter; Heinzmann, Sebastian; Brose, Marcia S.
Afiliação
  • Subbiah V; Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Hu MI; Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Mansfield AS; Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA.
  • Taylor MH; Developmental Cancer Therapeutics Laboratory, Earle A. Chiles Research Institute, Providence Portland Medical Center, Portland, Oregon, USA.
  • Schuler M; Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany.
  • Zhu VW; Department of Medicine, University of California Irvine, Orange, California, USA.
  • Hadoux J; Department of Endocrine Oncology, Gustave Roussy, Villejuif, France.
  • Curigliano G; Clinical Division of Early Drug Development, European Institute of Oncology, IRCCS, Milano, Italy.
  • Wirth L; Department of Oncology and Hemato-Oncology, University of Milano, Milano, Italy.
  • Gainor JF; Center for Head and Neck Cancers, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Alonso G; Center for Head and Neck Cancers, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Adkins D; Early Drug Development Unit, Vall d'Hebron University Hospital and Institute of Oncology, Barcelona, Spain.
  • Godbert Y; Division of Oncology, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Ahn MJ; Nuclear Medicine and Thyroid Oncology Department, Bergonié Institute Cancer Center, Bordeaux, France.
  • Cassier PA; Department of Hematology and Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
  • Cho BC; Department of Medical Oncology, Centre Léon Bérard, Lyon, France.
  • Lin CC; Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Zalutskaya A; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
  • Barata T; Blueprint Medicines Corporation, Cambridge, Massachusetts, USA.
  • Trask P; F. Hoffmann-La Roche Ltd., Basel, Switzerland.
  • Scalori A; Genentech, Inc., South San Francisco, California, USA.
  • Bordogna W; F. Hoffmann-La Roche Ltd., Welwyn Garden City, United Kingdom.
  • Heinzmann S; F. Hoffmann-La Roche Ltd., Basel, Switzerland.
  • Brose MS; F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Thyroid ; 34(1): 26-40, 2024 01.
Article em En | MEDLINE | ID: mdl-38009200
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pirazóis / Pirimidinas / Neoplasias da Glândula Tireoide / Carcinoma Neuroendócrino / Anilidas Limite: Adult / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pirazóis / Pirimidinas / Neoplasias da Glândula Tireoide / Carcinoma Neuroendócrino / Anilidas Limite: Adult / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article